Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Middleton

Showing results (491-500 of 522) with videos related to

Pageof 53
Sort By:
The Lancet. Oncology|June 23, 2023
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort studyBrian D Nicholson, Jason Oke, Pradeep S Virdee, et al.
Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
JAMA|July 12, 2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trialJohn P Neoptolemos, Malcolm J Moore, Trevor F Cox, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Cancer Research|August 30, 2014
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signalingShan Gao, Ilirjana Bajrami, Clare Verrill, et al.
Gastroenterology|June 20, 2021
Interferon-Gamma-Producing CD8<sup>+</sup> Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-ColitisSarah C Sasson, Stephanie M Slevin, Vincent T F Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
Nature Communications|May 17, 2022
Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2019
Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III TrialAngela M Hong, Gerald B Fogarty, Kari Dolven-Jacobsen, et al.
Pageof 53

Showing results (491-500 of 522) with videos related to

Sort By:
Pageof 53
The Lancet. Oncology|June 23, 2023
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort studyBrian D Nicholson, Jason Oke, Pradeep S Virdee, et al.
Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
JAMA|July 12, 2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trialJohn P Neoptolemos, Malcolm J Moore, Trevor F Cox, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Cancer Research|August 30, 2014
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signalingShan Gao, Ilirjana Bajrami, Clare Verrill, et al.
Gastroenterology|June 20, 2021
Interferon-Gamma-Producing CD8<sup>+</sup> Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-ColitisSarah C Sasson, Stephanie M Slevin, Vincent T F Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
Nature Communications|May 17, 2022
Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2019
Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III TrialAngela M Hong, Gerald B Fogarty, Kari Dolven-Jacobsen, et al.
Pageof 53